ImmuCell (ICCC) Competitors $3.57 -0.03 (-0.83%) (As of 10:15 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ICCC vs. CGEN, ADVM, PYXS, CHRS, CRDL, OTLK, RPTX, IFRX, VTYX, and PLXShould you be buying ImmuCell stock or one of its competitors? The main competitors of ImmuCell include Compugen (CGEN), Adverum Biotechnologies (ADVM), Pyxis Oncology (PYXS), Coherus BioSciences (CHRS), Cardiol Therapeutics (CRDL), Outlook Therapeutics (OTLK), Repare Therapeutics (RPTX), InflaRx (IFRX), Ventyx Biosciences (VTYX), and Protalix BioTherapeutics (PLX). These companies are all part of the "pharmaceutical products" industry. ImmuCell vs. Compugen Adverum Biotechnologies Pyxis Oncology Coherus BioSciences Cardiol Therapeutics Outlook Therapeutics Repare Therapeutics InflaRx Ventyx Biosciences Protalix BioTherapeutics ImmuCell (NASDAQ:ICCC) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, community ranking, analyst recommendations, dividends, earnings and institutional ownership. Do analysts prefer ICCC or CGEN? Compugen has a consensus target price of $4.00, indicating a potential upside of 181.69%. Given Compugen's stronger consensus rating and higher possible upside, analysts clearly believe Compugen is more favorable than ImmuCell.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Compugen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in ICCC or CGEN? 13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 12.2% of Compugen shares are owned by institutional investors. 6.6% of ImmuCell shares are owned by insiders. Comparatively, 9.5% of Compugen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media favor ICCC or CGEN? In the previous week, ImmuCell and ImmuCell both had 3 articles in the media. Compugen's average media sentiment score of 1.02 beat ImmuCell's score of 0.18 indicating that Compugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmuCell 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Compugen 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, ICCC or CGEN? ImmuCell has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Compugen has a beta of 2.64, suggesting that its stock price is 164% more volatile than the S&P 500. Which has stronger valuation and earnings, ICCC or CGEN? ImmuCell has higher earnings, but lower revenue than Compugen. ImmuCell is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuCell$17.47M1.82-$5.78M-$0.50-7.14Compugen$33.46M3.79-$18.75M$0.0271.00 Does the MarketBeat Community prefer ICCC or CGEN? Compugen received 187 more outperform votes than ImmuCell when rated by MarketBeat users. However, 73.33% of users gave ImmuCell an outperform vote while only 64.30% of users gave Compugen an outperform vote. CompanyUnderperformOutperformImmuCellOutperform Votes12173.33% Underperform Votes4426.67% CompugenOutperform Votes30864.30% Underperform Votes17135.70% Is ICCC or CGEN more profitable? Compugen has a net margin of 2.67% compared to ImmuCell's net margin of -15.99%. Compugen's return on equity of 2.62% beat ImmuCell's return on equity.Company Net Margins Return on Equity Return on Assets ImmuCell-15.99% -15.32% -8.81% Compugen 2.67%2.62%1.36% SummaryCompugen beats ImmuCell on 14 of the 17 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get ImmuCell News Delivered to You Automatically Sign up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ICCC vs. The Competition Export to ExcelMetricImmuCellDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.81M$2.21B$5.08B$8.80BDividend YieldN/A0.75%5.02%4.07%P/E Ratio-7.143.9191.2813.60Price / Sales1.8240.841,226.2187.40Price / CashN/A14.8239.4536.27Price / Book1.213.076.906.33Net Income-$5.78M$29.98M$118.83M$225.93M7 Day Performance-0.83%-1.67%-1.92%-0.96%1 Month Performance0.56%-10.46%-3.75%1.06%1 Year Performance-22.39%-15.85%31.37%26.59% ImmuCell Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ICCCImmuCell0.5144 of 5 stars$3.57-0.8%N/A-22.1%$31.81M$17.47M-7.1475CGENCompugen2.7226 of 5 stars$1.42-0.7%$4.00+181.7%+121.5%$126.72M$33.46M71.5068Positive NewsADVMAdverum Biotechnologies4.1779 of 5 stars$6.08-1.5%$27.83+357.8%-32.5%$126.46M$3.60M0.00190Analyst ForecastShort Interest ↓PYXSPyxis Oncology1.0178 of 5 stars$2.08-45.5%$10.00+380.8%+165.3%$123.70MN/A-1.9660Analyst ForecastNews CoverageGap DownHigh Trading VolumeCHRSCoherus BioSciences3.8318 of 5 stars$1.07-2.8%$6.13+472.6%-46.9%$123.24M$257.24M0.00246Gap DownCRDLCardiol Therapeutics2.7497 of 5 stars$1.50-3.8%$8.75+483.3%+81.1%$122.40M$60,000.00-4.0020Analyst ForecastAnalyst RevisionNews CoverageOTLKOutlook Therapeutics1.2029 of 5 stars$5.13-2.8%$48.20+839.6%-40.0%$121.38MN/A-0.4920RPTXRepare Therapeutics2.672 of 5 stars$2.85+0.4%$10.00+250.9%-44.7%$121.15M$51.13M0.00180IFRXInflaRx3.0863 of 5 stars$2.03-0.5%$8.00+294.1%+34.2%$119.53M$70,000.000.0060Gap UpVTYXVentyx Biosciences2.4892 of 5 stars$1.69-2.0%$10.00+493.5%-27.1%$119.15MN/A-0.7373PLXProtalix BioTherapeuticsN/A$1.61-4.9%N/A+22.0%$118.29M$65.49M-13.00200Analyst Upgrade Related Companies and Tools Related Companies CGEN Alternatives ADVM Alternatives PYXS Alternatives CHRS Alternatives CRDL Alternatives OTLK Alternatives RPTX Alternatives IFRX Alternatives VTYX Alternatives PLX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ICCC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuCell Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuCell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ICCC Stock Alerts